A Study of Zilovertamab Vedotin (MK-2140) as Monotherapy and in Combination in Participants With Aggressive and Indolent B-cell Malignancies (MK-2140-006)
The purpose of this study is to assess the safety and tolerability of zilovertamab
vedotin as monotherapy and in combination in participants with select B-cell lymphomas
including mantle cell lymphoma (MCL), Richter's transformation lymphoma (RTL), follicular
lymphom...
Age: 18 years - 66+
Gender: All
A Study of JNJ-80948543, a T Cell Redirecting Antibody, in Non-Hodgkin Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL)
The purpose of this study is to characterize safety and to determine the putative recommended
Phase 2 dose(s) (RP2D[s]) and optimal dosing schedule(s) of JNJ-80948543 in Part A (Dose
Escalation) and to further characterize the safety of JNJ-80948543 at the putative ...
Age: 18 years - 66+
Gender: All
A Study of JNJ-80948543, a T-cell Redirecting CD79b x CD20 x CD3 Trispecific Antibody, in Participants With Non-Hodgkin Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL)
The purpose of this study is to characterize safety and to determine the putative
recommended Phase 2 dose(s) (RP2D[s]), optimal dosing schedule(s) and route(s) of
administration of JNJ-80948543 in Part A (Dose Escalation) and to further characterize
the safety of JN...
Age: 18 years - 66+
Gender: All
Polatuzumab Vedotin in Combination With Chemotherapy in Subjects With Richter's Transformation
This study evaluates the effectiveness and safety of Polatuzumab vedotin plus infusional
chemoimmunotherapy containing rituximab, etoposide, prednisone, cyclophosphamide and
hydroxydaunorubicin. This is a single arm study. Enrolled patients will receive up to six
cyc...
Age: 18 years - 66+
Gender: All
Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL Study
This phase III trial compares early treatment with venetoclax and obinutuzumab versus
delayed treatment with venetoclax and obinutuzumab in patients with newly diagnosed
high-risk chronic lymphocytic leukemia or small lymphocytic lymphoma. Venetoclax is in a
class of...
Age: 18 years - 66+
Gender: All
A Study of JNJ-64264681 in Participants With Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia
The purpose of the study is to determine the recommended Phase 2 dose(s) (RP2D[s]) in B cell
non-Hodgkin lymphoma (NHL) and chronic lymphocytic leukemia (CLL) in Part 1 and to evaluate
the safety of JNJ-64264681 at the RP2D(s) in Part 2.
Age: 18 years - 66+
Gender: All